section name header

Table 105-2

Antiretroviral Drugs Used in the Treatment of HIV Infection

DrugStatusIndicationDose in CombinationSupporting DataToxicity
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors
Zidovudine (AZT, azidothymidine, Retrovir, 3'azido-3'-deoxythymidine)LicensedTreatment of HIV infection in combination with other antiretroviral agents200 mg q8h or 300 mg bid19 vs 1 death in original placebo-controlled trial in 281 patients with AIDS or ARCAnemia, granulocytopenia, myopathy, lactic acidosis, hepatomegaly with steatosis, headache, nausea, nail pigmentation, lipid abnormalities, lipoatrophy, hyperglycemia
Prevention of maternal-fetal HIV transmission In pregnant women with CD4+ T cell count 200/µL, AZT PO beginning at weeks 14-34 of gestation plus IV drug during labor and delivery plus PO AZT to infant for 6 weeks decreased transmission of HIV by 67.5% (from 25.5% to 8.3%), n = 363
Lamivudine (Epivir, 2'3'-dideoxy-3'-thiacytidine, 3TC)LicensedIn combination with other antiretroviral agents for the treatment of HIV infection

150 mg bid

300 mg qd

In combination with AZT superior to AZT alone with respect to changes in CD4+ T cell counts in 495 patients who were zidovudine-naïve and 477 patients who were zidovudine-experienced; overall CD4+ T cell counts for the zidovudine group were at baseline by 24 weeks, while in the group treated with zidovudine plus lamivudine, they were 10-50 cells/µL above baseline; 54% decrease in progression to AIDS/death compared with AZT aloneFlare of hepatitis in HBV-co-infected patients who discontinue drug
Emtricitabine (FTC, Emtriva)LicensedIn combination with other antiretroviral agents for the treatment of HIV infection200 mg qdComparable to stavudine in combination with didanosine and efavirenz in 571 treatment-naïve patients; similar to 3TC in combination with AZT or stavudine + NNRTI or PI in 440 patients doing well for 12 weeks on a 3TC regimenHepatotoxicity in HBV-co-infected patients who discontinue drug, skin discoloration
Abacavir (Ziagen)LicensedFor treatment of HIV infection in combination with other antiretroviral agents300 mg bidAbacavir + AZT + 3TC equivalent to indinavir + AZT + 3TC with regard to viral load suppression (~60% in each group with <400 HIV RNA copies/mL plasma) and CD4+ T cell increase (~100/µL in each group) at 24 weeksHypersensitivity reaction In HLA-B5701+ individuals (can be fatal); fever, rash, nausea, vomiting, malaise or fatigue, and loss of appetite
Tenofovir (Viread)LicensedFor use in combination with other antiretroviral agents when treatment is indicated300 mg qdReduction of ~0.6 log in HIV-1 RNA levels when added to background regimen in treatment-experienced patientsRenal, osteomalacia, flare of hepatitis in HBV-co-infected patients who discontinue drug
Non-Nucleoside Reverse Transcriptase Inhibitors
Nevirapine (Viramune)LicensedIn combination with other antiretroviral agents for treatment of progressive HIV infection

200 mg/d × 14 days then 200 mg bid

or

400 mg extended release qd

Increase in CD4+ T cell count, decrease in HIV RNA when used in combination with nucleosidesSkin rash, hepatotoxicity
Efavirenz (Sustiva)LicensedFor treatment of HIV infection in combination with other antiretroviral agents600 mg qhsEfavirenz + AZT + 3TC comparable to indinavir + AZT + 3TC with regard to viral load suppression (a higher percentage of the efavirenz group achieved viral load <50 copies/mL, but the discontinuation rate in the indinavir group was unexpectedly high, accounting for most treatment “failures”); CD4 cell increase (~140/µL in each group) at 24 weeksRash, dysphoria, elevated liver function tests, drowsiness, abnormal dreams, depression, lipid abnormalities, potentially teratogenic
Etravirine (Intelence)LicensedIn combination with other antiretroviral agents in treatment-experienced patients whose HIV is resistant to nonnucleoside reverse transcriptase inhibitors and other antiretroviral medications200 mg bidHigher rates of HIV RNA suppression to <50 copies/mL (56% vs 39%); greater increases in CD4+ T cell count (89 vs 64 cells) compared to placebo when given in combination with an optimized background regimenRash, nausea, hypersensitivity reactions
Rilpivirine (Edurant)LicensedIn combination with other drugs in previously untreated patients when treatment is indicated.25 mg qdNoninferior to efavirenz with respect to suppression at week 48 in 1368 treatment-naive individuals except in patients with pretherapy HIV RNA levels >100,000 where it was inferiorNausea, dizziness, somnolence, vertigo, less CNS toxicity and rash than Efavirenz
Protease Inhibitors

Ritonavir (Norvir)

Licensed

In combination with other antiretroviral agents for treatment of HIV infection when treatment is warranted

600 mg bid (also used in lower doses as pharmacokinetic booster)

Reduction in the cumulative incidence of clinical progression or death from 34% to 17% in patients with CD4+ T cell count <100/µL treated for a median of 6 months

Nausea, abdominal pain, hyperglycemia, fat redistribution, lipid abnormalities, may alter levels of many other drugs, paresthesias, hepatitis

Atazanavir (Reyataz)

Licensed

For treatment of HIV infection in combination with other antiretroviral agents

400 mg qd or300 mg qd + ritonavir100 mg qd when given with efavirenz

Comparable to efavirenz when given in combination with AZT + 3TC in a study of 810 treatment-naïve patients; comparable to nelfinavir when given in combination with stavudine + 3TC in a study of 467 treatment-naïve patients

Hyperbilirubinemia, PR prolongation, nausea, vomiting, hyperglycemia, fat maldistribution, rash transaminase elevations, renal stones

Darunavir (Prezista)LicensedIn combination with 100 mg ritonavir for combination therapy in treatment-experienced adults600 mg + 100 mg ritonavir twice daily with foodAt 24 weeks, patients with prior extensive exposure to antiretrovirals treated with a new combination including darunavir showed a -1.89-log change in HIV RNA levels and a 92-cell increase in CD4+ T cells compared with -0.48 log and 17 cells in the control armDiarrhea, nausea, headache, skin rash, hepatotoxicity, hyperlipidemia, hyperglycemia
Entry Inhibitors
Enfuvirtide (Fuzeon)LicensedIn combination with other agents in treatment-experienced patients with evidence of HIV-1 replication despite ongoing anti-retroviral therapy90 mg SC bidIn treatment of experienced patients, superior to placebo when added to new optimized background (37% vs 16% with <400 HIV RNA copies/mL at 24 weeks; + 71 vs + 35 CD4+ T cells at 24 weeks)Local injection reactions, hypersensitivity reactions, increased rate of bacterial pneumonia
Maraviroc (Selzentry)LicensedIn combination with other antiretroviral agents in adults infected with only CCR5-tropic HIV-1150-600 mg bid depending on concomitant medications (see text)At 24 weeks, among 635 patients with CCR5-tropic virus and HIV-1 RNA >5000 copies/mL despite at least 6 months of prior therapy with at least 1 agent from 3 of the 4 antiretroviral drug classes, 61% of patients randomized to maraviroc achieved HIV RNA levels <400 copies/mL compared with 28% of patients randomized to placeboHepatotoxicity, nasopharyngitis, fever, cough, rash, abdominal pain, dizziness, musculoskeletal symptoms
Integrase Inhibitor
Raltegravir (Isentress)LicensedIn combination with other antiretroviral agents400 mg bidAt 24 weeks, among 436 patients with 3-class drug resistance, 76% of patients randomized to receive raltegravir achieved HIV RNA levels <400 copies/mL compared with 41% of patients randomized to receive placeboNausea, headache, diarrhea, CPK elevation, muscle weakness, rhabdomyolysis

Elvitegravir

Licensed

In combination with other antiretroviral agents

1 tablet daily

Noninferior to raltegravir or atazanavir/ritonavir in treatment-experienced patients.

Diarrhea, nausea, upper respiratory infections, headache

Dolutegravir (Tivicay)

Licensed

In combination with other antiretroviral agents

50 mg daily for treatment-naïve patients; 50 mg twice daily for treatment-experienced patients or those also receiving efavirenz or rifampin

Noninferior to raltegravir, superior to efavirenz or darunavir/ritonavir

Insomnia, headache, hypersensitivity reactions, hepatotoxicity

Abbreviations: ARC, AIDS-related complex; NRTIs, nonnucleoside reverse transcriptase inhibitors.